A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 47,000 shares of NBIX stock, worth $6.42 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
47,000
Previous 36,300 29.48%
Holding current value
$6.42 Million
Previous $5 Million 8.28%
% of portfolio
0.0%
Previous 0.0%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$114.58 - $153.15 $117 Million - $157 Million
1,023,651 Added 138.16%
1,764,590 $203 Million
Q2 2024

Aug 14, 2024

SELL
$130.86 - $143.19 $13.1 Million - $14.4 Million
-100,379 Reduced 11.93%
740,939 $102 Million
Q1 2024

May 15, 2024

BUY
$130.4 - $143.74 $95.1 Million - $105 Million
729,318 Added 651.18%
841,318 $116 Million
Q4 2023

Feb 14, 2024

SELL
$106.07 - $132.76 $66.2 Million - $82.9 Million
-624,207 Reduced 84.79%
112,000 $14.8 Million
Q3 2023

Nov 14, 2023

SELL
$94.02 - $117.1 $53.6 Million - $66.8 Million
-570,066 Reduced 43.64%
736,207 $82.8 Million
Q2 2023

Aug 14, 2023

BUY
$89.53 - $104.87 $74.5 Million - $87.2 Million
831,881 Added 175.36%
1,306,273 $123 Million
Q1 2023

May 15, 2023

BUY
$94.11 - $123.02 $27.2 Million - $35.5 Million
288,824 Added 155.64%
474,392 $48 Million
Q4 2022

Feb 14, 2023

SELL
$106.72 - $127.06 $5.34 Million - $6.36 Million
-50,078 Reduced 21.25%
185,568 $22.2 Million
Q3 2022

Nov 14, 2022

BUY
$92.03 - $107.81 $21.7 Million - $25.4 Million
235,646 New
235,646 $25 Million
Q1 2022

May 16, 2022

SELL
$72.45 - $94.81 $52.9 Million - $69.2 Million
-729,731 Reduced 88.69%
93,098 $8.73 Million
Q4 2021

Feb 14, 2022

SELL
$79.65 - $106.22 $1.69 Million - $2.25 Million
-21,172 Reduced 2.51%
822,829 $70.1 Million
Q3 2021

Nov 15, 2021

BUY
$86.18 - $99.03 $15.2 Million - $17.4 Million
176,015 Added 26.35%
844,001 $80.9 Million
Q2 2021

Aug 16, 2021

SELL
$89.43 - $102.27 $41.8 Million - $47.8 Million
-467,361 Reduced 41.16%
667,986 $65 Million
Q1 2021

May 17, 2021

SELL
$87.57 - $119.4 $1.06 Million - $1.45 Million
-12,160 Reduced 1.06%
1,135,347 $110 Million
Q4 2020

Feb 16, 2021

BUY
$86.91 - $108.33 $72.7 Million - $90.6 Million
836,009 Added 268.38%
1,147,507 $110 Million
Q3 2020

Nov 16, 2020

BUY
$96.16 - $135.15 $16.1 Million - $22.6 Million
167,143 Added 115.79%
311,498 $30 Million
Q2 2020

Aug 14, 2020

SELL
$85.09 - $130.36 $72.6 Million - $111 Million
-852,854 Reduced 85.52%
144,355 $17.6 Million
Q1 2020

May 15, 2020

BUY
$75.11 - $113.76 $43 Million - $65.2 Million
573,054 Added 135.1%
997,209 $86.3 Million
Q4 2019

Feb 14, 2020

BUY
$86.8 - $118.57 $21.2 Million - $28.9 Million
243,978 Added 135.41%
424,155 $45.6 Million
Q3 2019

Nov 14, 2019

BUY
$83.82 - $101.5 $10.4 Million - $12.6 Million
124,617 Added 224.29%
180,177 $16.2 Million
Q2 2019

Aug 14, 2019

BUY
$72.24 - $91.27 $344,584 - $435,357
4,770 Added 9.39%
55,560 $4.69 Million
Q1 2019

May 15, 2019

SELL
$69.31 - $91.53 $26.9 Million - $35.6 Million
-388,808 Reduced 88.45%
50,790 $0
Q3 2018

Nov 13, 2018

BUY
$98.88 - $125.85 $2.32 Million - $2.95 Million
23,431 Added 5.63%
439,598 $0
Q2 2018

Aug 10, 2018

BUY
$75.3 - $105.99 $7.38 Million - $10.4 Million
97,981 Added 30.79%
416,167 $0
Q1 2018

May 11, 2018

SELL
$75.88 - $92.43 $16.6 Million - $20.3 Million
-219,221 Reduced 40.79%
318,186 $26.4 Million
Q4 2017

Feb 09, 2018

BUY
$58.53 - $77.59 $18.8 Million - $24.9 Million
320,800 Added 148.1%
537,407 $41.7 Million
Q3 2017

Nov 09, 2017

BUY
$47.97 - $61.28 $10.4 Million - $13.3 Million
216,607
216,607 $13.3 Million

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $13.1B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.